financetom
Business
financetom
/
Business
/
Federal Bank's Shyam Srinivasan expects NIMs to sustain; credit growth to be around 8-10%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Federal Bank's Shyam Srinivasan expects NIMs to sustain; credit growth to be around 8-10%
Jan 20, 2021 7:28 AM

Control on cost of funds lead to a strong show from Federal Bank's net interest margins (NIMs) as the lender reported a 12-quarter high. Shyam Srinivasan, MD and CEO of Federal Bank said that the bank could sustain these margins going forward.

"We have been guiding it for quite some time. It is driven by the business mix shift. We have tried to retailise the franchise, we have tired higher margin businesses and most importantly our low cost deposit growth is quite spectacular. So driven by the mix change, liability business more granular, and our portfolio quality is strong, so the reversal of interest income was also quite muted. So the blend, maybe this quarter a little more flattering at 3.22 percent. We would be somewhere in the 3.17-3.20 zone – that has been the improvement last year same time. At the beginning of the calendar year 2020, it was about 3.04 percent, it has been moving quite steadily," Srinivasan told CNBC-TV18.

On asset quality, he said, "In a normal year, for the last 3-4 years, we would have slippages of about Rs 1,500-1,600 crore in a full year. For the

Going forward, Srinivasan expects credit growth to be around 8-10 percent. "The full year loan growth we do believe will be between 8-10 percent depending on how the next 70 days go. So, if it is going to be full year 8-10 percent, then last quarter has to be quite strong which reflects the underlying momentum. If you take Q3, every sequential month we saw pick up. In most businesses December was 120 percent of January. If that run rate continues, we do believe credit growth should be between 8-10 percent," he said.

To know more watch the video.

(Edited by : Jerome Anthony)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boeing says it is ready to negotiate new agreement after workers vote to strike
Boeing says it is ready to negotiate new agreement after workers vote to strike
Sep 13, 2024
SEATTLE, Sept 12 (Reuters) - Boeing ( BA ) said late on Thursday it was ready to get back to negotiations to reach a new agreement after its U.S. West Coast factory workers voted down a tentative contract deal and said they would go on strike. International Association of Machinists and Aerospace Workers (IAM) members voted 96% in favor of...
Prudential Financial Unit Secures Abu Dhabi License, Opens Local Office
Prudential Financial Unit Secures Abu Dhabi License, Opens Local Office
Sep 13, 2024
07:30 AM EDT, 09/12/2024 (MT Newswires) -- Prudential Financial's ( PRU ) investment management unit PGIM said Thursday it has opened an office in Abu Dhabi after receiving a Financial Services Permission to operate in Abu Dhabi Global Market, the city's financial center. Mohammed Abdulmalek was recently named head of the Middle East for the asset manager and chairman of...
Murano Global Investments Closes $300 Million Senior Notes Offering
Murano Global Investments Closes $300 Million Senior Notes Offering
Sep 13, 2024
04:27 AM EDT, 09/13/2024 (MT Newswires) -- Murano Global Investments ( MRNO ) said late Thursday it closed an offering of $300 million of 11% senior secured notes due 2031. The company plans to use the proceeds to prepay existing debt, fund a debt service reserve account, fund working capital and support hotel completion costs, it said. Price: 7.30, Change:...
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy
Halozyme Therapeutics Says FDA Approves Tecentriq Hybreza Cancer Immunotherapy
Sep 13, 2024
04:08 AM EDT, 09/13/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said late Thursday the US Food and Drug Administration approved Swiss healthcare company Roche's cancer immunotherapy, Tecentriq Hybreza, in combination with Halozyme's Enhanze drug delivery technology. The product is a combination of the atezolizumab antibody and Halozyme's human hyaluronidase enzyme, rHuPH20. The product will be available in the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved